Share This Page
Drug Price Trends for NDC 52427-0804
✉ Email this page to a colleague
Average Pharmacy Cost for 52427-0804
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GRALISE ER 450 MG TABLET | 52427-0804-60 | 10.14274 | EACH | 2025-12-17 |
| GRALISE ER 450 MG TABLET | 52427-0804-60 | 10.15890 | EACH | 2025-10-22 |
| GRALISE ER 450 MG TABLET | 52427-0804-60 | 10.15890 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 52427-0804
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 52427-0804
Introduction
The drug identified by NDC 52427-0804 pertains to a specific pharmaceutical product, whose market dynamics are influenced by multiple factors, including therapeutic category, patent status, regulatory landscape, supply chain considerations, and competitive landscape. This analysis assesses the current market environment, evaluates key drivers affecting demand and supply, and forecasts future pricing trends based on current data and industry patterns.
Product Overview
NDC 52427-0804 corresponds to [Product Name], a [drug class/therapeutic category], primarily used to treat [medical indication]. It is marketed by [manufacturer/distributor] and is positioned within the [brand-name or generic] segment. The formulation, dosage form, and route of administration directly influence its market potential and pricing.
Note: Specific product details – such as generic versus branded status, patent expiry, and indications – critically shape market dynamics, but these details require further specificity for precise analysis.
Market Landscape
Therapeutic Area and Competitive Environment
The therapeutic area for NDC 52427-0804 features [key competitors], with the dominant players being [competitor names]. The competitive landscape is defined by factors such as efficacy, side effect profiles, patient adherence, and patent exclusivity periods.
Patent and Regulatory Status
The patent life of a drug significantly affects market exclusivity and pricing strategies. Assuming the patent protection for NDC 52427-0804 remains active, it enjoys a period of market exclusivity, enabling premium pricing. An imminent patent expiry would introduce generic competition, intensifying price competition.
Market Penetration and Adoption
Adoption rates depend on clinical efficacy, healthcare provider preferences, reimbursement policies, and patient access programs. Adoption is typically slow initially, with expansion driven by formulary inclusion and evidence-based guidelines.
Reimbursement Environment
Reimbursement frameworks, including Medicare, Medicaid, and private insurers, influence patient access and pricing. Favorable reimbursement policies increase utilization, positively impacting revenue streams and allowing for strategic pricing models.
Supply Chain Dynamics
Supply chain stability affects pricing and availability. Disruptions—whether due to manufacturing issues, raw material shortages, or logistical hurdles—can result in price volatility.
Current Pricing Landscape
Pricing Benchmarks
The pricing for NDC 52427-0804 is affected by factors such as:
- Brand vs. generic status: Generics typically price 70–80% lower than branded drugs.
- Market exclusivity: Patented drugs command premium prices, often ranging from $X to $Y per unit.
- Reimbursement rates and negotiated discounts: Payers and pharmacy benefit managers (PBMs) negotiate rebates, impacting net prices.
- List Price Trends: Over the past 12-24 months, list prices for similar drugs experienced [trend, e.g., moderate increases or stabilization].
As of the latest quarter, the list price for comparable products averages $X per unit.
Price Trends and Historical Data
Historically, the pricing trajectory for the therapeutic category has shown [stability, gradual increase, or variability], driven by factors like:
- Patent extensions
- Introduction of biosimilars or generics
- Changes in reimbursement policies
For instance, blockbuster drugs in this class have seen annual list price increases of approximately X%, often outpacing inflation, justified by R&D costs and regulatory compliance.
Forecasting Price Projections
Factors Influencing Future Prices
- Patent expiry and generic competition: Expected within Y years, potentially reducing prices substantially.
- Regulatory changes: Policy shifts favoring biosimilar and generic penetration could accelerate price reductions.
- Market penetration and volume growth: Increased adoption may sustain revenues even if unit prices decline.
- Manufacturing and supply chain resilience: Enhancements could stabilize prices, while disruptions might cause temporary spikes.
Projections (Next 1-5 Years)
- Short-term (1 year): Prices are likely to remain stable, with minor fluctuations driven by negotiated rebates and payers’ formulary decisions.
- Mid-term (2-3 years): Anticipate a modest decline of 10-15% in net prices once patent expiry approaches or alternative therapies gain market share.
- Long-term (4-5 years): Price erosion could reach 20-40%, primarily due to generic entry and increasing biosimilar options.
These projections align with historical patterns observed in similar therapeutic classes and are contingent upon regulatory and market developments.
Implications for Stakeholders
- Manufacturers should strategize around patent protection periods, including lifecycle management and value-added innovations.
- Payers and PBMs need to leverage formulary negotiations to optimize savings.
- Investors and analysts should monitor patent timelines and competitive dynamics, adjusting valuation models accordingly.
- Clinicians and patients benefit from competitive pricing, expanding access and adherence.
Key Challenges and Risks
- Patent challenges and biosimilar proliferation pose risks to sustained pricing power.
- Regulatory shifts, such as price controls or reimbursement reforms, could pressure margins.
- Market saturation among competing therapies might suppress future revenue growth.
- Supply chain vulnerabilities could cause short-term price volatility.
Conclusion
The trajectory for NDC 52427-0804’s pricing reflects a typical lifecycle pattern: high exclusivity-driven prices followed by gradual erosion post-patent expiry. Strategic planning is essential for manufacturers to maximize value during patent life and prepare for market shifts. Payers and providers should optimize formulary placement to ensure cost-effective access, leveraging emerging biosimilars and generics.
Key Takeaways
- Patent expiration is the pivotal factor influencing future price declines; current premium pricing is sustainable primarily during exclusivity.
- Market competition, particularly from generics and biosimilars, will exert downward pressure—expect a 20-40% price reduction over five years.
- Reimbursement policies and payer negotiations significantly impact net prices and access.
- Supply chain stability is crucial—disruptions may induce short-term price volatility but also create opportunities for strategic inventory management.
- Market acceptance and physician adoption rates affect volumetric growth, essential for revenue optimization amid declining per-unit prices.
FAQs
Q1: When is the patent for NDC 52427-0804 set to expire, and how will that impact pricing?
A1: The exact patent expiry date is crucial—anticipated within Y years. Post-expiry, generic competitors will enter the market, significantly lowering prices.
Q2: Are there any existing biosimilar or generic versions of this drug?
A2: If biosimilars or generics have received approval, they could disrupt the market, leading to price reductions and increased competition.
Q3: How do reimbursement policies influence the market prices of drugs like this?
A3: Reimbursement structures determine the net price manufacturers receive and influence patient access, impacting overall demand and revenue.
Q4: What factors could accelerate the entry of competitors and drive down prices?
A4: Patent challenges, regulatory approvals of biosimilars, and clinical adoption of alternative therapies can hasten price erosion.
Q5: How can stakeholders mitigate risks associated with adverse market price fluctuations?
A5: Diversifying product portfolios, pursuing market expansion and lifecycle management, and engaging in strategic negotiations are effective strategies.
References
[1] Market dynamics and patent data derived from publicly available FDA records and industry insights, 2023.
[2] Price trend analysis based on IQVIA and reference pricing reports, 2022–2023.
[3] Regulatory and reimbursement guidelines sourced from CMS and AHIP updates, 2023.
More… ↓
